Full-Time

Medical Director

Mpmd, Pspv

Takeda

Takeda

10,001+ employees

Global biopharmaceutical firm; R&D-driven NMEs

No salary listed

Bengaluru, Karnataka, India

Hybrid

Hybrid work arrangement; occasional schedule alignment with US Eastern Time.

MD, Doctor of Osteopathic Medicine (DO)

Category
Biology & Biotech
Required Skills
Biostatistics
Risk Management
Data Analysis

Get referred to Takeda

See people who can refer or advise you

Requirements
  • M.D. or D.O. or internationally recognized equivalent, with relevant clinical experience following post-graduate training and appropriate grounding and knowledge of general medicine, epidemiology and biostatistics.
  • Board certification and licensure preferred.
Responsibilities
  • Serve as Global Safety Lead (GSL) and the Company-wide subject matter expert in patient for assigned pharmaceutical, biological, drug-device combination products. Accountable for defining and executing the safety strategy and for delivering major safety outputs across the product lifecycle.
  • Lead PSPV Global Safety Team (GST) and Safety Management Team (SMT), ensuring alignment on safety priorities, timely decision-making, and clear accountability across functions.
  • Represent the cross-functional program team as a product safety profile and risk mitigation expert for internal (e.g., Takeda Safety Board) and external (e.g., Independent Data Monitoring Committee, regulatory agencies).
  • Manage cross-functional assessment of benefit-risk profile and ensure consistent, accurate, and timely communication of safety information to internal and external stakeholders.
  • Provide proactive, science-based guidance on emerging safety issues and risk mitigation strategies, ensuring early identification and mitigation of potential risks.
  • Analyze and interpret safety data from various sources including non-clinical, clinical, post-marketing real-world evidence, and scientific literature.
  • Conduct signal detection, monitoring, evaluation, interpretation, and management, ensuring compliance with global regulatory expectations and internal procedures.
  • Develop strategy for and lead preparation of responses to safety-related inquiries from regulatory agencies and ethics committees, ensuring responses are scientifically robust, consistent, and inspection-ready.
  • Ensure communication of all safety information that may impact the benefit-risk profile of assigned products to senior management and governance bodies.
  • Provide medical safety expertise, medical interpretation, review, and authorship of appropriate sections for critical documents (e.g., protocols and amendments, informed consent forms (ICFs), investigator brochures (IBs), IMPDs, clinical studies reports (CSR), Health Hazard Evaluations (HHE), Signal Evaluation Reports (SER), INDs, NDAs, BLAs, and CTAs) in collaboration with cross-functional colleagues.
  • Integrate safety considerations into clinical development program for assigned products and development compounds, including input into study design, statistical analysis plans, and key endpoints to ensure appropriate safety characterization.
  • Manage benefit-risk profile, including authoring and maintaining regulatory documents such as Risk Management Plans (RMPs).
  • Collaborate and with and influence cross-functional partners, including Clinical Development, Regulatory Affairs, Quality Assurance, Medical Affairs, Marketing, Manufacturing, and Legal, to ensure aligned and consistent safety messaging and decision-making.
  • Interact with Regulatory Authorities as part of a cross-functional team to support submissions and effectively defend safety positions during regulatory interactions.
  • Ensure up-to-date representation of safety information in Company Core Data Sheet (including Reference Safety Information) and Investigator Brochure, as well as other labeling documents.
  • Demonstrate knowledge of regional and global pharmacovigilance regulations and evolving safety expectations.
  • Support PSPV in maintaining a high-performing, inspection-ready global safety organization, ensuring full compliance with worldwide regulations and internal standards.
  • Train, mentor, and provide scientific guidance to Pharmacovigilance Physicians and Safety Scientists, helping to build capability and ensure consistency of safety assessments.
  • Maintain professional knowledge and accreditation by active participation in continuing medical education activities and contribute to a culture of continuous learning and scientific.
  • Preferred to have capability in leveraging quantitative methodologies and emerging technologies, including artificial intelligence, to enhance signal detection and safety surveillance, while ensuring scientific validity and regulatory acceptability.
Desired Qualifications
  • Board certification and licensure preferred.
  • Capability in leveraging quantitative methodologies and emerging technologies, including artificial intelligence, to enhance signal detection and safety surveillance, while ensuring scientific validity and regulatory acceptability

Takeda is a global biopharmaceutical company focused on discovering and delivering medicines and vaccines to improve patient health. It relies on extensive research and development to create new molecular entities (NMEs) and bring them to market, aiming for up to 15 product launches through FY2024 from a pipeline of 11 NMEs. Revenue comes mainly from selling pharmaceutical products, supported by about 41,000 third-party suppliers worldwide. The company differentiates itself through a deep history (over 240 years), a broad portfolio of global brands, and a patient-centric approach that places patients’ needs at the center of its operations while pursuing environmental sustainability. Takeda’s goal is to advance health globally by turning scientific innovations into accessible therapies, maintaining long-term growth through steady product innovation and responsible operations.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Get referred to Takeda

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 FDA approval for MIMRYLO unlocks near-term U.S. oncology revenue.
  • Takeda expects ORZEYFUL U.S. launch by November 2026, pending DEA scheduling.
  • Q1 FY2026 new launches grew 22.6%, offsetting mature-brand declines and supporting guidance.

What critics are saying

  • May 18, 2026 AMITIZA verdict exposed Takeda to $2.6 billion treble-damage risk.
  • Takeda plans 4,500 FY2026 cuts, signaling launch execution pressure and organizational churn.
  • Patent erosion crushed VYVANSE sales 60.7% at constant currency in Q1 FY2026.

What makes Takeda unique

  • ORZEYFUL became the first orexin agonist approved for narcolepsy type 1 in 2026.
  • MIMRYLO offers first-in-class hepcidin mimetic therapy for polycythemia vera after FDA approval.
  • Takeda pairs global scale with Japanese discovery, including Shonan-led neurology innovation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Associated Press
Sep 9th, 2026
Trialbee unveils AI-powered patient screening chatbot at DPHARM 2026

Trialbee, a patient recruitment platform provider, will present at DPHARM 2026 in Boston on 15-16 September. The Swedish-American company will unveil AI-powered patient screening in its Honey Platform, enabling conversational AI chatbots to conduct initial candidate assessments whilst giving patients the option to speak with recruitment specialists. Trialbee will present jointly with pharmaceutical company Takeda on integrating their respective platforms to build research-ready patient communities that extend beyond single trials. The company will also participate in a panel discussing AI applications at clinical trial sites. The Honey Platform has added several AI features this year, including candidate summaries, duplicate detection, and recruitment data analysis. Trialbee supports over 6,000 research sites across 50 countries and reports a 91% repeat business rate with biopharmaceutical companies.

Associated Press
Sep 9th, 2026
Onco360 selected as specialty pharmacy partner for rare blood cancer drug MIMRYLO

Onco360, a US independent speciality pharmacy, has been selected by Takeda Pharmaceuticals as an ultra-narrow limited distribution partner for MIMRYLO (rusfertide). The treatment is indicated for erythrocytosis in adults with polycythemia vera. MIMRYLO is a mimetic of the endogenous hormone hepcidin that blocks the iron transporter ferroportin. This inhibition reduces iron availability for red blood cell production, resulting in lower hematocrit levels. The drug's approval was based on the phase 3 VERIFY study, a global, randomised, open-label clinical trial. The primary endpoint measured the proportion of patients achieving response during weeks 20-32, defined as the absence of phlebotomy eligibility. The most common adverse reactions were injection site reactions at 56% and anaemia at 16%.

Yahoo Finance
Aug 31st, 2026
Takeda wins FDA approval for first-in-class blood cancer drug, triggering $275M payment to Protagonist

The FDA approved Takeda Pharmaceutical's MIMRYLO (rusfertide) for polycythemia vera, a blood cancer causing red blood cell overproduction. The first-in-class drug functions as a hepcidin mimetic, regulating iron distribution to control hematocrit levels and prevent life-threatening complications like strokes and pulmonary embolisms. Approval was based on the Phase 3 VERIFY study involving 293 patients. Those receiving MIMRYLO alongside standard care achieved superior hematocrit control, reduced phlebotomy needs, and improved fatigue compared to placebo. Takeda commercialises MIMRYLO under a 2024 agreement with Protagonist Therapeutics, which discovered the drug. The approval triggers $275 million in payments to Protagonist—a $200 million opt-out fee plus $75 million milestone. Protagonist remains eligible for up to $875 million in additional milestones and tiered royalties of 14% to 29% on worldwide net sales.

Associated Press
Aug 28th, 2026
US FDA approves Takeda's Mimrylo for polycythemia vera treatment

Takeda has received US FDA approval for MIMRYLO (rusfertide), a first-in-class treatment for erythrocytosis in adults with polycythemia vera (PV), a blood cancer. The drug is a hepcidin mimetic that regulates iron distribution and red blood cell overproduction to control hematocrit levels. The approval was supported by the Phase 3 VERIFY study involving 293 PV patients. Results showed MIMRYLO plus standard care demonstrated higher response rates than placebo, including better hematocrit control, reduced phlebotomy needs, and improved fatigue scores. PV affects approximately 90,000 people in the US. An estimated 78% of patients experience uncontrolled hematocrit with current standard care. The most common adverse events were injection site reactions and anaemia. MIMRYLO is administered once weekly via subcutaneous injection. Takeda is working with regulators outside the US for potential global availability.

Associated Press
Aug 24th, 2026
Japan approves Orzeyful as first medicine targeting narcolepsy type 1's underlying cause

Takeda announced Japan's Ministry of Health, Labour and Welfare has approved ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults. The oral medication is the first to address the underlying orexin deficiency causing the disease, rather than just managing individual symptoms. Narcolepsy type 1 is a chronic neurological condition characterised by excessive daytime sleepiness, cataplexy, disrupted sleep, and other symptoms that significantly impact patients' daily lives. Diagnostic delays average more than 10 years. The approval follows global Phase 3 trials showing statistically significant improvements across the full range of symptoms. Common side effects included insomnia, urinary urgency and frequency, and excessive saliva. ORZEYFUL is also approved in China and the United States. Takeda developed the first-in-class orexin receptor 2 agonist in its Japanese laboratories and plans to launch the treatment quickly.